Press Release
Arcadia Biosciences Announces First-Quarter 2020 Financial Results and Business Highlights
"This is an extraordinary moment in time for all of us," said
"Despite some headwinds generated by COVID-19, we are pleased with the robust quarter of strategic partnerships and acquisitions in the hemp space, including grower-facing partners like Grow West® and
"Today's hemp supply chain is still evolving and clearly will need advances to reach its full commercial potential," said Plavan. "We believe we can be an attractive partner to companies throughout that supply chain. In addition to our organic growth strategies, we are now poised to accelerate shareholder value creation through acquisitive and strategic growth opportunities in the processing, manufacturing and brand segments of the hemp value chain to create a leading, vertically-integrated platform focused on the highest technology, quality and transparency in hemp and hemp products.
"To help us navigate this emerging market, Arcadia has reached into the sector and is working with strategic advisors, including
Q1 2020 Operating and Business Highlights
- More Than
$3 Million in Seed Purchase Commitments for GoodHemp™. Within two months post launch of the GoodHemp seed catalog, Arcadia secured more than$3 million in initial seed purchase commitments, reflecting strong market demand for quality genetics in the emerging hemp industry. Revenues from these initial purchase commitments will be recognized when the seeds are delivered to growers, between second and fourth quarter of 2020. This revenue, along with that expected from follow-on commitments, will contribute meaningfully to the$10 million in total expected revenues for 2020, as forecasted in the company's financial guidance. - Established GoodHemp Innovation Partners Platform. To support the company's strategy to become a market leader in high-value hemp innovations and ensure the continued success of the GoodHemp line, Arcadia established the GoodHemp Innovation Partners Platform, a select group of growers who will work closely with Arcadia's team of regional agronomists to further the shared understanding of GoodHemp seed performance at industrial scale throughout the production season. This unique go-to-market approach utilizes a hub model with initial centers in
Hawaii , thePacific Northwest ,Southern California ,Northern California , the Desert Southwest and the Mountain West. Innovation partners receive exclusive access to the team of breeders, geneticists and computational biologists at Arcadia's R&D headquarters inDavis and serve as a hemp production advisory board highlighting grower challenges to inform Arcadia's future breeding efforts. They also have early access to developmental seed varieties and will help validate innovations under real farm conditions. Strategic Retailer Partnership to Introduce GoodHemp Seeds toCalifornia Growers . Arcadia announced a new strategic partnership with Grow West, one of the largest independent marketers of agricultural products inCalifornia , andButtonwillow Warehouse Company (BWC), a family owned and operated fertilizer and crop protection products company in Central andSouthern California , to introduce Arcadia'sUSDA -compliant GoodHemp seed line toCalifornia growers. Grow West and BWC will bring their collective grower relationships to Arcadia's GoodHemp Innovation Partners Platform, and Arcadia gains access to every production acre in the state, including topCalifornia cultivators who rely on the crop and pest control advisors of these two companies to make important decisions throughout the growing season.- Archipelago Ventures™ Partnered with
Vivion Specialties, Inc. to Distribute Hawaiian Hemp Products inNorth America . Recently Arcadia announced a new partnership betweenArchipelago Ventures , its joint venture with Legacy Ventures Hawaii, andVivion Specialties, Inc. (VSI), a North American specialty ingredient supplier. VSI will serve as Archipelago's North American distributor, managing the stateside marketing and sales of sun-grown Hawaiian hemp ingredients in key markets like food and beverage, human and pet nutrition and personal care. VSI has a network of 18 sales regions in theU.S. andCanada and is known for its proprietary VivAssure® purity validation process, which tests every ingredient and provides a detailed Certificate of Analysis of its contents. The collaboration will deliver rigorously tested and lab-certified CBD ingredients, providing high quality and transparency for discerning retailers and shoppers throughoutNorth America . U.S. Patents Granted for HighFiber Wheat with Improved Yield. Arcadia expanded its GoodWheat™ patent portfolio to include an allele that improves yield in high fiber, resistant starch wheat. In multi-year field studies, wheat breeding lines carrying the higher-yielding allele produced an average of 6 to 9 percent higher yields, with some resulting in as much as 30 percent higher yields. Field trials further indicated there may be other benefits to this innovation, including reduction in sensitivity to the damaging effects of cold at specific growth stages. The higher-yielding allele is the output of Arcadia's ArcaTech technology platform and is the latest among a suite of patents Arcadia has licensed to Arista Cereal Technologies andBay State Milling inNorth America . These improvements to the crop yield and production efficiency are an example of the companies' continuing plans to expand the adoption and market footprint of high fiber, resistant starch wheat.- Verdeca Registers Early Adopters for HB4 Program at Expoagro 2020. For the second year in a row in March, Verdeca showcased pre-commercial HB4 soybeans varieties at Expoagro 2020,
Argentina's largest farm show. At Verdeca's pavilion, growers were able to inspect field plots of HB4 soybeans demonstrating the trait stack's tolerance to drought, salinity and glufosinate. Early adopters in the HB4 program can begin testing the trait in their own fields in preparation for commercial launch following import approval fromChina . These pre-commercial varieties are currently being multiplied on close to 7,400 acres, with the potential for more than 100,000 additional acres available for seed multiplication during the next crop season.
Q2 Business Highlights
Randy Shultz , Ph.D. Promoted to Chief Technology Officer. In early April, Arcadia promotedRandy Shultz , Ph.D. to the role of chief technology officer. Shultz joined Arcadia in 2019 as head of research and development and has played an instrumental role in accelerating novel non-GM hemp varieties with ArcaTech™, Arcadia's proprietary rapid prototyping and development platform. In this new, elevated position, Shultz will oversee the execution of Arcadia's strategic, multi-year plan to become a market leader in high-value hemp innovations, as well as continue to advance next generation products through the company's GoodWheat pipeline.- Expanded Intellectual Property Protection for GoodWheat Portfolio. Arcadia recently announced it has further strengthened its intellectual property and wheat technology portfolio with four additional
U.S. patents. TheU.S. Patent and Trademark Office awarded the company two patents for extending the shelf life of whole wheat by minimizing hydrolytic and oxidative rancidity. The company also received notices of allowance for two additional patents extending earlier claims surrounding the extended shelf life of wheat and reduced gluten grains. The new patents bring the total number of patents in Arcadia's GoodWheat portfolio of non-genetically modified (non-GM ) wheat varieties to 22.
|
|||||||
Financial Snapshot |
|||||||
(Unaudited) |
|||||||
($ in thousands) |
|||||||
Three Months Ended |
|||||||
2020 |
2019 |
Favorable / (Unfavorable) |
|||||
$ |
% |
||||||
Total Revenues |
309 |
158 |
151 |
96% |
|||
Total Operating Expenses |
6,099 |
4,376 |
(1,723) |
(39)% |
|||
Loss From Operations |
(5,790) |
(4,218) |
(1,572) |
(37)% |
|||
Net Income (Loss) Attributable to Common Stockholders |
2,525 |
(12,612) |
15,137 |
120% |
Revenues
In the first quarter of 2020, revenues were
Operating Expenses
In the first quarter of 2020, operating expenses were
Net Income Attributable to Common Stockholders
Net income attributable to common stockholders for the first quarter of 2020 was
Conference Call and Webcast
The company has scheduled a conference call for
Interested participants can join the conference call using the following numbers:
|
+1-844-243-4690 |
International Dial-In: |
+1-225-283-0138 |
Passcode: |
3560919 |
A live webcast of the conference call will be available on the "Investors" section of the Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.
About
Safe Harbor Statement
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to the company's revenue from seed sales and its total revenue for 2020, the company's access to growers, and the company's plans,, commercial products and collaborations. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the price and demand for the company's wheat and hemp related products are lower than expected; the company's and its partners' and affiliates' ability to develop and sell commercial products incorporating its traits, and complete the regulatory review process for such products; the company's and it partners' ability to fulfill current and follow-on purchase commitments; the company's compliance with laws and regulations that impact the company's business, and changes to such laws and regulations; the growth of the global wheat and hemp markets; the successful integration of the company's business with the businesses of any future partners; the potential impact of COVID-19 on the company's business; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the
|
|||
Condensed Consolidated Balance Sheets |
|||
(Unaudited) |
|||
(In thousands, except share data) |
|||
|
|
||
Assets |
|||
Current assets: |
|||
Cash and cash equivalents |
$ 12,973 |
$ 8,417 |
|
Short-term investments |
3,045 |
16,915 |
|
Accounts receivable |
309 |
602 |
|
Inventories, net — current |
5,971 |
1,794 |
|
Prepaid expenses and other current assets |
1,460 |
712 |
|
Total current assets |
23,758 |
28,440 |
|
Property and equipment, net |
2,540 |
1,799 |
|
Right of use asset |
5,654 |
1,963 |
|
Inventories, net — noncurrent |
273 |
364 |
|
Other noncurrent assets |
23 |
8 |
|
Total assets |
$ 32,248 |
$ 32,574 |
|
Liabilities and stockholders' equity |
|||
Current liabilities: |
|||
Accounts payable and accrued expenses |
$ 4,912 |
$ 4,685 |
|
Amounts due to related parties |
16 |
40 |
|
Notes payable — current |
31 |
24 |
|
Unearned revenue — current |
17 |
42 |
|
Operating lease liability — current |
526 |
611 |
|
Other current liabilities |
306 |
306 |
|
Total current liabilities |
5,808 |
5,708 |
|
Notes payable — noncurrent |
130 |
107 |
|
Operating lease liability — noncurrent |
5,312 |
1,497 |
|
Common stock warrant liabilities |
6,775 |
14,936 |
|
Other noncurrent liabilities |
2,000 |
2,000 |
|
Total liabilities |
20,025 |
24,248 |
|
Stockholders' equity: |
|||
Common stock, |
49 |
49 |
|
Additional paid-in capital |
215,612 |
214,826 |
|
Accumulated other comprehensive income |
— |
1 |
|
Accumulated deficit |
(204,646) |
(207,171) |
|
Total |
11,015 |
7,705 |
|
Non-controlling interest |
1,208 |
621 |
|
Total stockholders' equity |
12,223 |
8,326 |
|
Total liabilities and stockholders' equity |
$ 32,248 |
$ 32,574 |
|
|||
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) |
|||
(Unaudited) |
|||
(In thousands, except share and per share data) |
|||
Three Months Ended |
|||
2020 |
2019 |
||
Revenues: |
|||
Product |
$ 154 |
$ 107 |
|
License |
100 |
— |
|
Royalty |
30 |
— |
|
Contract research and government grants |
25 |
51 |
|
Total revenues |
309 |
158 |
|
Operating expenses: |
|||
Cost of product revenues |
132 |
59 |
|
Research and development |
2,244 |
1,505 |
|
Selling, general and administrative |
3,723 |
2,812 |
|
Total operating expenses |
6,099 |
4,376 |
|
Loss from operations |
(5,790) |
(4,218) |
|
Interest expense |
(3) |
— |
|
Other income, net |
72 |
120 |
|
Change in fair value of common stock warrant and common stock adjustment feature liabilities |
8,161 |
(8,495) |
|
Net income (loss) before income taxes |
2,440 |
(12,593) |
|
Income tax provision |
(17) |
(19) |
|
Net income (loss) |
2,423 |
(12,612) |
|
Net loss attributable to non-controlling interest |
(102) |
— |
|
Net income (loss) attributable to common stockholders |
$ 2,525 |
$ (12,612) |
|
Net income (loss) per share attributable to common stockholders: |
|||
Basic and diluted |
0.29 |
$ (2.64) |
|
Weighted-average number of shares used in per share calculations: |
|||
Basic |
8,651,213 |
4,776,540 |
|
Diluted |
8,674,610 |
4,776,540 |
|
Other comprehensive loss, net of tax |
|||
Unrealized losses on available-for-sale securities |
(1) |
— |
|
Other comprehensive loss |
(1) |
— |
|
Comprehensive income (loss) attributable to common stockholders |
$ 2,524 |
$ (12,612) |
|
|||
Condensed Consolidated Statements of Cash Flows |
|||
(Unaudited) |
|||
(In thousands) |
|||
Three Months Ended |
|||
2020 |
2019 |
||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|||
Net income (loss) |
$ 2,423 |
$ (12,612) |
|
Adjustments to reconcile net income (loss) to cash used in operating activities: |
|||
Change in fair value of common stock warrant and common stock adjustment feature liabilities |
(8,161) |
8,495 |
|
Depreciation |
74 |
34 |
|
Lease amortization |
223 |
172 |
|
Net amortization of investment premium |
(39) |
(39) |
|
Stock-based compensation |
772 |
422 |
|
Write down of inventory |
59 |
— |
|
Changes in operating assets and liabilities: |
|||
Accounts receivable |
293 |
86 |
|
Inventories |
(4,145) |
39 |
|
Prepaid expenses and other current assets |
(748) |
200 |
|
Other noncurrent assets |
(15) |
— |
|
Accounts payable and accrued expenses |
227 |
(538) |
|
Amounts due to related parties |
(24) |
(16) |
|
Unearned revenue |
(25) |
(40) |
|
Operating lease payments |
(184) |
(172) |
|
Net cash used in operating activities |
(9,270) |
(3,969) |
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|||
Purchases of property and equipment |
(778) |
(88) |
|
Purchases of investments |
(1,292) |
(6,690) |
|
Proceeds from sales and maturities of investments |
15,200 |
9,200 |
|
Net cash provided by investing activities |
13,130 |
2,422 |
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|||
Payments of offering costs relating to |
— |
(16) |
|
Payments of deferred offering costs |
— |
(5) |
|
Principal payments on notes payable |
(7) |
— |
|
Proceeds from ESPP purchases |
14 |
8 |
|
Capital contributions received from non-controlling interest |
689 |
— |
|
Net cash provided by (used in) financing activities |
696 |
(13) |
|
Net increase (decrease) in cash and cash equivalents |
4,556 |
(1,560) |
|
Cash and cash equivalents — beginning of period |
8,417 |
11,998 |
|
Cash and cash equivalents — end of period |
$ 12,973 |
$ 10,438 |
|
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
|||
Cash paid for income taxes |
$ — |
$ 2 |
|
Cash paid for interest |
$ 3 |
$ — |
|
NONCASH INVESTING AND FINANCING ACTIVITIES: |
|||
Fixed assets acquired with notes payable |
$ 37 |
$ — |
|
Offering costs in accounts payable and accrued expenses at end of period |
$ — |
$ 7 |
|
Deferred offering costs in accounts payable and accrued expenses at end of period |
$ — |
$ 18 |
|
Right of use assets obtained in exchange for new operating lease liabilities |
$ 3,836 |
$ 2,328 |
|
Purchases of fixed assets included in accounts payable and accrued expenses |
$ — |
$ 13 |
View original content to download multimedia:http://www.prnewswire.com/news-releases/arcadia-biosciences-announces-first-quarter-2020-financial-results-and-business-highlights-301058865.html
SOURCE
Press Contact: Lisa Weser, Trailblaze, lisa@trailblaze.co, or Investor Contact: Pam Haley, Chief Financial Officer, ir@arcadiabio.com